Search for content, post, videos

BioInvent receives IND approval

The U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) for the Phase I/IIa clinical study of the immuno-modulatory anti-TNFR2 antibody BI-1808. “FDA approval of the Phase I/IIa study of BI-1808 is another important milestone for BioInvent as we continue to b
Already a subscriber Login

You have read all your free articles, to continue reading subscribe to read the rest of this content.